Skip to content
Open access

SNP rs7430456 mediated LINC00578 drives triple negative breast cancer through regulating miR-143-5p expression

Jul 2026 · Hereditas · Vol 163 · 0 citations · 29 references
Medicine

TL;DR

LINC00578 rs7430456 is associated with breast cancer susceptibility, and LINC00578 promotes TNBC progression via sponging miR-143-5p, being a potential biomarker and therapeutic target for breast cancer, particularly TNBC.

Abstract

A large number of cancer-related single-nucleotide polymorphisms (SNPs) are distributed in the genomic regions of long non-coding RNAs (lncRNAs), yet the mechanisms linking them to cancer risk have not been fully clarified so far. This study explored LINC00578 rs7430456’s association with breast cancer susceptibility and LINC00578’s role/mechanism in triple-negative breast cancer (TNBC). A total of 480 breast cancer patients and 460 controls were enrolled. LINC00578 rs7430456 genotyping and LINC00578 expression detection via RT-qPCR were performed. Functional assays (proliferation, migration, invasion) were conducted in TNBC cell lines, and the LINC00578-miR-143-5p interaction was explored by dual-luciferase reporter assay. LINC00578 rs7430456 G allele and AG/GG genotypes reduced breast cancer risk. LINC00578 was upregulated in breast cancer (especially TNBC) with an AUC of 0.873 for diagnosis. LINC00578 knockdown inhibited TNBC cell proliferation, migration, and invasion. LINC00578 sponged miR-143-5p, and miR-143-5p mediated its oncogenic effects. LINC00578 rs7430456 is associated with breast cancer susceptibility, and LINC00578 promotes TNBC progression via sponging miR-143-5p, being a potential biomarker and therapeutic target for breast cancer, particularly TNBC.

Read PDF

Similar papers

Aug 2026

Elevated Expression of LINC02257 and LINC00659 in Breast Cancer is Associated with Poor Survival and Immune Cell Infiltration

This study found that LINC02257 and LINC00659 are upregulated in BC and are associated with malignancy-related genes and patient survival, suggesting their potential as therapeutic targets and prognostic biomarkers.

Fatemeh Badzohre, Azin Azadfekr, Farnoosh Akbari et al. · 0 citations
Open access Aug 2026

Long Noncoding RNAs (lncRNAs) as Biomarkers of Prognosis in TNBC and Non-TNBC Breast Cancer Patients

This computational study identifies several candidate lncRNAs associated with clinical outcomes in breast cancer, which should be interpreted as preliminary candidates, which require future validation and functional studies to determine their biological roles and evaluate their potential as prognostic biomarkers.

M. Acencio, Xin-Hui Wang, Flavia R. Rotea Mangone et al. · 0 citations
Open access Jan 2026

rs2357322 and rs17726078 Contribute to Breast Cancer Risk by Regulating DLX2 Expression

Recursion of the segment containing these two SNPs by CRISPR/Cas9 can significantly increase DLX2 mRNA and protein expression, cell proliferation, colony formation, migration, and wound healing, thus suggesting that the cis‐regulatory element is an attenuator for gene expression.

Xin-Xin Zhang, Hao Guo, Hai-Yan Li et al. · 0 citations
Aug 2026

The miR-338-5p/METTL3 axis regulates m6A modification to inhibit tumor progression in triple-negative breast cancer.

This study reveals post-transcriptional regulation of METTL3 by miR-338-5p by confirming a functional miR-338-5p/METTL3/m6A axis in TNBC and targeting this distinct regulatory axis represents a promising therapeutic strategy for TNBC.

Wen-Jia Chen, Ya Xu, Yang-Zheng Lan et al. · 0 citations
Open access Aug 2026

Uncovering genetic variations in HTR2A and miRNAs drivers of breast cancer risk in African American women

The findings suggest that HTR2A variants and miRNA profiles may serve as potential biomarkers for risk stratification and targeted therapeutic approaches in TNBC, and help scientists find better ways to detect and treat breast cancer in AA women.

Nicole Retland, Karl M. Thompson, Joseph I. Aubee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.